Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Gene editing breakthrough: One-Time infusion may free patients from lifelong blood transfusions

NCT ID NCT05577312

First seen Jan 18, 2026 · Last updated May 20, 2026 · Updated 20 times

Summary

This study tests a single-dose gene therapy (BRL-101) for people with transfusion-dependent beta-thalassemia, a severe blood disorder requiring regular transfusions. The treatment uses the patient's own blood stem cells, modified with CRISPR-Cas9, to help the body produce healthy red blood cells. The goal is to reduce or eliminate the need for transfusions. The study involves 39 participants aged 3-35 and will monitor safety and effectiveness for one year.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BETA-THALASSEMIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Chinese Academy of Medical Sciences

    Tianjin, Tianjin Municipality, China

  • Nanfang Hospital, Southern Medical University

    Guangzhou, Guangdong, 510510, China

  • The First Affiliated Hospital of Guangxi Medical University

    Nanning, Guangxi, 530021, China

  • Xiangya Hospital of Central South University

    Changsha, Hunan, 510510, China

Conditions

Explore the condition pages connected to this study.